Previously Announced Strategy Focus Prioritizes Opportunities in Rice and Biofragrance Products and Sustainable Ingredients with Initiatives Expected to Reduce Annual Net Cash Usage to Approximately $30M by 2026 Cibus Well Situated to Pursue Partner Funding to Support its Advanced Productivity Trait Portfolio SAN DIEGO, July 23, 2025 (GLOBE NEWSWIRE) -- Cibus, Inc. (Nasdaq: CBUS) (the "Company"), a leading agricultural technology company that develops plant traits to license to seed companies for royalties, ...

Group 1 - The company "Chip Superhero" has a 1,600 square meter intelligent warehouse for chips, with over 1,000 stock models and around 100 brands, totaling 50 million chips in stock valued at over 100 million [1] - The company operates an independent laboratory in Shenzhen, ensuring quality control (QC) for each material [1] - The company has served a total of 19,200 users and can complete transactions in as fast as half a day [4] Group 2 - The company is currently seeking to purchase specific chip models, including ST's STM32G071G8U6 (10K), ON's NCP1096PAG (9K), Fujitsu's MB85RC64TAPN-G AMEWE1 (15K), TDK's ICM-42688-P (28K), and Sensirion's SHT15 (2,500) [2] - The company is offering discounted sales on advantageous materials, such as Vishay's NTCLE100E3102TB0 with 282,000 pieces available from 2024 or later [3]

Core Insights - Cibus is advancing its gene editing technologies, particularly in rice and canola, with a focus on herbicide tolerance and disease resistance traits, targeting a commercial launch by 2027 [1][2] - Positive regulatory developments in Ecuador and the U.S. validate Cibus' gene editing technologies, enhancing its commercial prospects [1][2][7] - The company reported a significant increase in net loss for Q1 2025, primarily due to a goodwill impairment, while also showing progress in revenue generation [8][9][24] Company Developments - Cibus has achieved positive results in its Sclerotinia resistance program, demonstrating multiple modes of action against the disease in canola [1][4] - The USDA-APHIS has designated Cibus' canola disease resistance traits as not regulated, reinforcing the regulatory status of its RTDS technologies [1][2][7] - The company is expanding its trait development pipeline, with successful field trials and customer agreements in rice, including collaborations with major rice seed companies [5][7] Financial Performance - For Q1 2025, Cibus reported revenue of $1.034 million, up from $0.545 million in the same period last year [23][24] - Research and development expenses were $11.8 million, slightly down from $12.0 million year-over-year, while selling, general, and administrative expenses increased to $9.9 million [8][24] - The net loss for the quarter was $49.4 million, compared to $27.0 million in the previous year, largely due to a $21.0 million goodwill impairment [8][9][24] Regulatory and Market Progress - The California Rice Commission approved the planting of gene-edited rice, marking a significant milestone for Cibus in the U.S. market [7][9] - EU member states have endorsed a negotiating mandate on the regulation of plants obtained by New Genomic Techniques, facilitating discussions for legislative adoption [1][7] - Cibus plans to deliver initial traits to customers in California and Latin America by mid-2025 and the end of 2025, respectively [7][9]

Core Viewpoint - Cibus, Inc. has received regulatory confirmation from Ecuador's Ministry of Agriculture and Livestock that its herbicide tolerance traits in rice (HT1 and HT3) are equivalent to those developed through conventional breeding, allowing for further product development and commercialization in Ecuador [1][2][3] Company Overview - Cibus is a leading agricultural technology company focused on developing and licensing plant traits to seed companies, utilizing its Rapid Trait Development System™ (RTDS) to enable targeted genetic changes without recombinant DNA [2][5] - The company aims to address critical productivity and sustainability challenges for farmers, with a long-term focus on major global row crops such as canola, rice, and soybean [5] Regulatory Developments - The Ecuadorian Ministry of Agriculture and Livestock has determined that Cibus' HT1 and HT3 rice traits can proceed with registration and commercialization under existing laws, avoiding restrictions that apply to transgenic plants [2][4] - This regulatory decision is expected to facilitate the introduction of Cibus' herbicide tolerance traits in Latin American markets through partnerships with companies like Interoc [3][4] Market Implications - Cibus plans to collaborate with Interoc, which has expertise in rice seed genetics, to integrate HT1 and HT3 traits into elite rice lines, providing innovative weed management solutions to growers in Latin America [3][4] - The company believes that this regulatory approval in Ecuador will pave the way for pursuing similar clearances in other key Latin American markets [4]

编前：今年上海车展，混合动力车型持续火热，无论是在整车企业还是在零部件企业的展台上，车用动力多元化的发展趋势愈加明晰。在车展前不 久，浩思动力（ Horse Powertrain ）旗下子公司 Aurobay 极光湾科技凭借其革命性的高性能混动系统，荣获有 " 汽车界奥斯卡 " 之称的美国 PACE 大奖。这不 仅是 Aurobay 极光湾科技的成就，更是中国车用动力在全球汽车技术领域上的重大突破。浩思动力在上海车展完成首秀后，中国汽车报社总编辑桂俊松与 极光湾科技首席执行官王瑞平就此进行交流。 桂俊松：就在上海车展前不久， Aurobay 极光湾获得了被誉为 " 汽车界奥斯卡 " 的美国 PACE 大奖，我想这不仅是 Aurobay 极光湾的成就，更是中国汽车 动力技术进步与产业化成就的体现，请谈谈您的感受。 王瑞平：PACE大奖是由《美国汽车新闻》杂志主导的专业而且独立性很强的行业奖项，是全球汽车领域的顶级奖项。而且就像奥斯卡颁奖一样，直 到开奖那一刻，我们都并不知晓最终花落谁家。所以当得奖的消息传来，大家都十分振奋，也受到了极大的鼓舞。 桂俊松：在浩思动力这家合资公司中， Aurobay 极光湾科技的优 ...